Literature DB >> 7683725

5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.

T M Williams1, T M Ciccarone, S C MacTough, C S Rooney, S K Balani, J H Condra, E A Emini, M E Goldman, W J Greenlee, L R Kauffman.   

Abstract

A series of highly potent, structurally novel, non-nucleoside RT inhibitors has been described. Low nanomolar concentrations of 5-chloro-3-(phenylsulfonyl)-indole-2-carboxamide (1) inhibit the HIV-1 RT enzyme in vitro and HTLVIIIb viral spread in MT-4 human T-lymphoid cells. Good oral bioavailability was observed in rhesus monkeys upon oral dosing of 1 as a suspension in methocel. When compared to other non-nucleoside inhibitors (e.g. 15-18), 1 possesses improved inhibitory potency with respect to the wild-type RT, as well as the K103N and Y181C mutant enzymes. Additional studies within this class of inhibitors are in progress.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683725     DOI: 10.1021/jm00061a022

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  20 in total

1.  A new cascade halosulfonylation of 1,7-enynes toward 3,4-dihydroquinolin-2(1H)-ones via sulfonyl radical-triggered addition/6-exo-dig cyclization.

Authors:  Yi-Long Zhu; Bo Jiang; Wen-Juan Hao; Ai-Fang Wang; Jiang-Kai Qiu; Ping Wei; De-Cai Wang; Guigen Li; Shu-Jiang Tu
Journal:  Chem Commun (Camb)       Date:  2016-01-31       Impact factor: 6.222

Review 2.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

3.  High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme.

Authors:  Reynel Cancio; Romano Silvestri; Rino Ragno; Marino Artico; Gabriella De Martino; Giuseppe La Regina; Emmanuele Crespan; Samantha Zanoli; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.

Authors:  Mohammad Hassam; Adriaan E Basson; Dennis C Liotta; Lynn Morris; Willem A L van Otterlo; Stephen C Pelly
Journal:  ACS Med Chem Lett       Date:  2012-05-02       Impact factor: 4.345

5.  Synthesis of 3-sulfenyl- and 3-selenylindoles by the Pd/Cu-catalyzed coupling of N,N-dialkyl-2-iodoanilines and terminal alkynes, followed by n-Bu(4)NI-induced electrophilic cyclization.

Authors:  Yu Chen; Chul-Hee Cho; Feng Shi; Richard C Larock
Journal:  J Org Chem       Date:  2009-09-04       Impact factor: 4.354

6.  Ethyl 2-(3,4-dimethoxy-benz-yl)-1-phenyl-sulfonyl-1H-indole-3-carboxyl-ate.

Authors:  B Gunasekaran; Radhakrishnan Sureshbabu; A K Mohanakrishnan; G Chakkaravarthi; V Manivannan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-07-15

7.  Preformulation and Vaginal Film Formulation Development of Microbicide Drug Candidate CSIC for HIV prevention.

Authors:  Tiantian Gong; Wei Zhang; Michael A Parniak; Phillip W Graebing; Bernard Moncla; Phalguni Gupta; Kerry M Empey; Lisa C Rohan
Journal:  J Pharm Innov       Date:  2017-03-03       Impact factor: 2.750

8.  N-[(3-Phenylsulfanyl-1-phenylsulfonyl-1H-indol-2-yl)methyl]acetamide.

Authors:  S Thenmozhi; A Subbiahpandi; V Dhayalan; A K Mohanakrishnan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-04-10

9.  Phen-yl(1-phenyl-sulfonyl-1H-indol-2-yl)methanone.

Authors:  S Ranjith; A Subbiahpandi; E Govindan; V Dhayalan; A K Mohanakrishnan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-03-12

10.  The utility of self-emulsifying oil formulation to improve the poor solubility of the anti HIV drug CSIC.

Authors:  Nicholas C Obitte; Lisa C Rohan; Christianah M Adeyeye; Michael A Parniak; Charles O Esimone
Journal:  AIDS Res Ther       Date:  2013-05-31       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.